智通财经APP获悉，礼来(LLY.US)当地时间周三发布重要公告，其旗下抗肿瘤药物Verzenio在后期临床 试验中取得突破性进展。根据全球III期monarchE试验的主要总体生存期(OS)分析数据，这款已获美国 FDA批准的药物作为联合治疗方案的一部分，显著提升了特定乳腺癌患者的总体生存率。 礼来公司肿瘤事业部负责人雅各布·范纳登(Jacob Van Naarden)表示："这些数据进一步确立了Verzenio作 为淋巴结阳性高风险患者标准治疗方案的地位，也凸显出让所有符合条件患者及时接受治疗的重要 性。" 据披露，礼来计划在近期举办的医学会议上详细展示该研究成果，同时将论文投稿至权威学术期刊进行 同行评议，并着手与全球主要监管机构展开结果沟通。 该项国际多中心研究纳入超过5500例激素受体阳性(HR+)、HER2阴性、淋巴结阳性且高风险的早期乳 腺癌患者。试验结果显示，Verzenio联合内分泌治疗相较于单独使用内分泌疗法，在总体生存期这一关 键次要终点上实现了具有统计学显著性和临床意义的改善。 值得注意的是，该口服药物还在无侵袭性疾病生存期等主要研究指标中展现出持续获益，这一指标正是 monarchE ...

Core Viewpoint - Proton therapy is redefining breast cancer recovery by providing effective treatment without compromising the patient's future health and quality of life [1][5]. Group 1: Patient Experience and Benefits - A young HER2-positive breast cancer patient successfully underwent proton therapy, experiencing minimal side effects and expressing gratitude for the treatment's impact on her quality of life [1]. - Proton therapy has been successfully implemented for multiple breast cancer patients at Guangzhou Taihe Cancer Hospital, emphasizing its role in enhancing both longevity and quality of life [1]. Group 2: Suitable Patient Demographics - Proton therapy is particularly beneficial for left-sided breast cancer patients due to its ability to significantly reduce radiation exposure to the heart and coronary arteries [3]. - Patients requiring irradiation of the internal mammary lymph nodes, those with unique anatomical structures, young patients under 50, and those needing re-irradiation for local recurrence can also benefit from proton therapy [3][4]. Group 3: Advantages of Proton Therapy - The unique physical properties of proton therapy, such as the Bragg Peak, allow for precise targeting of tumors while minimizing damage to surrounding healthy tissues, which is crucial for protecting vital organs [5]. - Proton therapy reduces the risk of secondary cancers by limiting unnecessary radiation exposure to healthy tissues, making it especially important for younger patients with longer life expectancies [5][6]. - The treatment offers better dose distribution, potentially improving local control rates for complex cases [5]. Group 4: Treatment Applications - Proton therapy serves as an adjunctive treatment post-surgery, effectively targeting residual cancer cells while maximizing protection of the heart and lungs [7]. - It can be used as a curative option for patients unable to undergo surgery due to severe comorbidities, either alone or in combination with systemic therapies [8]. - Proton therapy can be integrated with other treatments, such as chemotherapy and targeted therapies, to enhance local toxicity control and optimize treatment outcomes [9].